Magnetic Resonance Elastography for the Noninvasive Staging of Liver Fibrosis

Huwart, Laurent; Sempoux, Christine; Vicaut, Éric; Salameh, Najat; Annet, Laurence; Danse, Étienne; Peeters, Frank; Beek, Leon C. ter; Rahier, Jacques; Sinkus, Ralph; Horsmans, Yves; Beers, Bernard E. Van

doi:10.1053/j.gastro.2008.03.076

Cited by 663 publications

(542 citation statements)

References 24 publications

Supporting

Mentioning

485

Contrasting

Unclassified

Order By: Relevance

“…107 A recent study in 133 patients with various liver diseases revealed stunning AUROC values between 0.985 and 0.998 for the diagnosis of fibrosis stages F Ն 2, F Ն 3, or F Ն 4, and superiority of MR elastography over ultrasound elastography or a combination of the serological AST over platelet ratio (APRI) combined with ultrasound elastography. 108 Hepatic inflammation and mechanical cholestasis are expected to be confounders as with ultrasound elastography, but studies are lacking.…”

Section: Noninvasive Means To Assess Liver Fibrosis and Fibrogenesismentioning

confidence: 99%

Targeting Liver Fibrosis

2009

View full text Add to dashboard Cite

We have made striking progress in our understanding of the biochemistry and cell biology that underlies liver fibrosis and cirrhosis, including the development of strategies and agents to prevent and reverse fibrosis. However, translation of this knowledge into clinical practice has been hampered by (1) the limitation of many in vitro and in vivo models to confirm mechanisms and to test antifibrotic agents, and (2) the lack of sensitive methodologies to quantify the degree of liver fibrosis and the dynamics of fibrosis progression or reversal in patients. Furthermore, whereas cirrhosis and subsequent decompensation are accepted hard clinical endpoints, fibrosis and fibrosis progression alone are merely plausible surrogates for future clinical deterioration. In this review we focus on an optimized strategy for preclinical antifibrotic drug development and highlight the current and future techniques that permit noninvasive assessment and quantification of liver fibrosis and fibrogenesis. The availability of such noninvasive methodologies will serve as the pacemaker for the clinical development and validation of potent antifibrotic agents. (HEPATOLOGY 2009;50:1294-1306

show abstract

Section: Noninvasive Means To Assess Liver Fibrosis and Fibrogenesismentioning

confidence: 99%

Targeting Liver Fibrosis

2009

View full text Add to dashboard Cite

show abstract

“…However, although it requires special software and equipment, it can be easily implemented on existing MR scanners with suitable alterations [141,142]. MRE has been compared to TE [143] as well as other noninvasive markers of fibrosis [144]. To evaluate the diagnostic capabilities of MRE, two high-quality meta-analyses have been performed comparing MRE with histology as the gold standard and had clearly defined inclusion and exclusion criteria, both using QUADAS scoring to evaluate quality [104,145] (Table 13).…”

Section: Magnetic Resonance Elastography (Mre)mentioning

confidence: 99%

“…Large population studies are still lacking. There were few studies comparing MRE to TE, but MRE had a higher technical success rate than TE and a better diagnostic accuracy (0.994 for F [ 2; 0.985 for F [ 3; 0.998 for F [ 4) [143].…”

Section: Magnetic Resonance Elastography (Mre)mentioning

confidence: 99%

Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update

et al. 2016

View full text Add to dashboard Cite

show abstract

“…1,2 Combined use of elastography and fibrosis markers may be a superior method. Algorithms for combined use of serum markers and elastography have been proposed, with specific cut-off values being used in the decision trees.…”

Section: Bayesian Prediction For Liver Fibrosis Staging: Combined Usementioning

confidence: 99%

“…Because the immediate treatment might not be available for patients with FHF in the clinical setting, whether delayed treatment remains beneficial would be more significant, as proposed by other researchers. 2 Given that pigs without cell transplantation could still survive for a mean of 2.9 days, we wonder whether the investigators examined the influence of different lengths of intervals on outcomes.…”

Section: Immediate Intraportal Transplantation Of Human Bone Marrow Mmentioning

confidence: 99%